Physician

Jeremy Aaron Ross, M.D.

According to 2025 Medicare claims, Jeremy Ross, M.D. (NPI: 1013250455) practices hematology/oncology in the Fort Worth-Arlington-Grapevine, TX market, with the plurality of this provider's patient population coming from Tarrant, TX. This provider's primary affiliated billing organization is ONCOLOGY-HEMATOLOGY CONSULTANTS PA (NPI: 1629021159; TIN: 752512142) and primary practice location at 76104-4611. Ross is affiliated with the Memorial Hermann Accountable Care Organization (ACO ID: A1175) and UT Southwestern Accountable Care Network (ACO ID: D0211), participating under both the MSSP and REACH models.

Ross' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 424 traditional Medicare patients, billed 157,760 HCPCS/CPT codes, and received $2,950,274 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,197 prescription claims across 179 beneficiaries totaling $2,534,901 in drug costs, led by Ibrance (Palbociclib). 2021 DME data shows 30 claims. Open Payments data shows 192 records totaling $149,173. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $8,101 to $2,950,274. Similarly, Part D prescription costs have moved sharply higher in recent years, from $14,277 to $2,534,901. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	34	104	$8,101
2017	17	38	$3,249
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	163	34,503	$393,853
2021	331	97,242	$960,399
2022	343	126,110	$1,427,380
2023	362	131,852	$1,772,234
2024	424	157,760	$2,950,274

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	35	213	$14,277
2016	26	69	$6,051
2017	N/R	33	$4,229
2018	14	25	$7,194
2019	11	33	$7,039
2020	41	97	$150,829
2021	95	476	$773,438
2022	115	709	$1,700,368
2023	149	820	$2,351,769
2024	179	1,197	$2,534,901

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	30	$1,178
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	92	494	$138
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	144	313	$97
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	77	296	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	79	132	$64
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	145	272	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ibrance	Palbociclib	27	756	$422,630
Cabometyx	Cabozantinib S-Malate	15	450	$386,345
Xtandi	Enzalutamide	20	600	$284,373
Tagrisso	Osimertinib Mesylate	14	420	$240,336
Revlimid	Lenalidomide	12	294	$187,903

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	192	$149,173	Regeneron Healthcare Solutions, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jeremy Aaron Ross, M.D.?

Tedicare shows public-source Medicare data for Jeremy Aaron Ross, M.D. (NPI 1013250455), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jeremy Aaron Ross, M.D. have ACO affiliation data?

Jeremy Aaron Ross, M.D. is shown with ACO affiliation data for Memorial Hermann Accountable Care Organization (MSSP, ACO ID A1175) and UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Jeremy Aaron Ross, M.D.?

Jeremy Aaron Ross, M.D. is linked to ONCOLOGY-HEMATOLOGY CONSULTANTS PA (billing NPI 1629021159) in the available physician profile data.

Does Jeremy Aaron Ross, M.D. have Open Payments data?

Jeremy Aaron Ross, M.D. has 192 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.